SCHEDULE 13G/A: Farallon Capital Discloses 7.9% Stake in Revolution Medicines, Citing Late Filing Due to Administrative Error

Farallon Capital and its affiliated entities have disclosed a beneficial ownership of 7.9% in Revolution Medicines, Inc. common stock, totaling 13,262,045 shares, in a Schedule 13G/A filing that was submitted late due to an administrative error.

Summary

• Farallon Capital Partners, L.P., along with several other Farallon Capital affiliated funds and their general partners and managing members (collectively, the "Reporting Persons"), have filed an Amendment No. 2 to Schedule 13G regarding their beneficial ownership in Revolution Medicines, Inc.
• The Reporting Persons collectively beneficially own an aggregate of 13,262,045 shares of Revolution Medicines, Inc. Common Stock, which includes 13,248,692 directly held shares and 120,085 Common Stock Purchase Warrants exercisable into approximately 13,351 shares.
• This aggregate ownership represents 7.9% of Revolution Medicines, Inc.'s outstanding common stock.
• The filing indicates that the statement is a late submission due to an inadvertent administrative error.
• The shares are held by various Farallon Funds, including Farallon Capital Partners, L.P., Farallon Capital Institutional Partners, L.P., Farallon Capital Institutional Partners II, L.P., Farallon Capital Institutional Partners III, L.P., Four Crossings Institutional Partners V, L.P., Farallon Capital Offshore Investors II, L.P., Farallon Capital (AM) Investors, L.P., Farallon Capital F5 Master I, L.P., and Farallon Healthcare Partners Master, L.P.
• Farallon Partners, L.L.C., as the general partner of several funds, and other general partners and individual managing members/managers, are deemed beneficial owners with shared voting and dispositive power over these shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While a large institutional holding can be positive, the primary content is a routine ownership disclosure, albeit with a negative note regarding the late filing. It does not contain performance or strategic updates for the issuer.

Positives

• A significant stake (7.9%) held by a prominent institutional investor like Farallon Capital may signal confidence in Revolution Medicines, Inc.'s long-term prospects.

Negatives

• The filing was submitted late due to an inadvertent administrative error, indicating a compliance lapse on the part of the reporting entity.

Risks

• The late filing of the Schedule 13G due to an administrative error represents a compliance risk for Farallon Capital and its related entities.

Future Outlook

NA

Industry Context

This filing reflects a passive investment by a multi-strategy hedge fund in a biotechnology company, a common practice for institutional investors seeking exposure to specific sectors or growth opportunities. It does not provide specific insights into Revolution Medicines, Inc.'s operational performance or industry trends beyond the fact that it is an investable entity for such funds.

Management Changes

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional holding by Farallon Capital may be viewed positively as a vote of confidence, but the late filing could raise minor concerns about compliance processes of the reporting entity.
• Regulatory Authorities: The late filing due to administrative error could draw attention from the SEC regarding compliance with reporting deadlines.

Key Dates

Keywords

Revolution Medicines, Farallon Capital, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Investment Management, Healthcare Sector